Investors warned about South African energy company
PSG Wealth has reaffirmed its sell recommendation on Renergen shares despite a probable buyout of the energy company.
Renergen is South Africa’s first onshore natural gas explorer and the first integrated producer of both liquefied helium (LHe) and liquefied natural gas (LNG).
Its most significant asset is the Virginia Gas Project, which it claims contains one of the richest helium concentrations recorded globally.
The company has claimed the project has production rights for 187,000 hectares of gas fields in Welkom, Virginia, and Theunissen, in the Free State.
Although the company recently saw its revenue increase by over 80% from R29 million to R52.1 million in the year ending February 28, 2025, its attributable loss widened to over R235 million.
Protea Capital Management founder and CEO Jean Pierre Verster previously said he would have liked to short Renergen if he could, but the stock was too illiquid to do so.
The group may have received a saving grace after the US-based ASP Isotopes offered to acquire Renergen shares.
That said, the acquisition will not be in cash. Renergen shareholders will receive ASP Isotopes shares listed on the JSE.
ASP Isotopes is a materials company dedicated to developing technology and processes for producing isotopes in multiple industries.
However, its financial results are also problematic. It reported a net loss of $33.5 million (R600 million) in 2024—far larger than Renergen’s loss.
If this arrangement does not go through, there is a backup “standby offer,” which would see it acquire 100% of the issued share capital.
Renergen CEO Stefano Marani would join ASP Isotopes as the CEO of Electronics and Space, based in Austin, Texas, joining the company’s board.
Renergen
Despite the purchase offer, PSG Wealth Equity Analyst Marnus Piekaar has not changed his mind on the stock.
He noted that the offer from ASP Isotopes has progressively become less worthwhile for Renergent shareholders since it was announced in early July.
The current offer gives roughly 0.1 of APS Isotope shares for each Renergen share, which works out to around R16.53, as per Piekaar’s analysis for 28 July.
This represents a slight premium on Renergen’s R16 closing price.
However, the offer price has changed daily due to the movement of ASP Isotope’s share price and the current ZAR/USD exchange rate.
Piekaar said this is a risk for Renergen shareholders as the ASP Isotope share moves quite a bit.
At the end of July, the difference between the offer and Renergen’s stock value was relatively small, at around 3%, with Renergen’s share price rising due to the offer.
He also noted that the offer’s terms are incredibly conditional, such as creditors extending terms. The deal could also be delayed, which creates further risk to shareholders.
If the deal does not go through, Renergen will continue to face its serious challenges. This includes successful fundraising to fund its operations.
The company’s production history also presents operational and execution risks. Given that its products are commodities, it also faces commodity price and currency risks.
The company has also breached its debt covenants. Although creditors have relaxed some of the covenants, debt repayment will still need to occur.
With this in mind, PSG Financial Services has maintained its sell recommendation on the stock.
This comes despite the company’s intrinsic value rising to R10.5 per share, which is due to the likelihood of the ASP Isoptope deal going through following shareholder approval.
This is still well below the current stock price.
Renergen Financials
Loading ...